Free Biopharma Investor Posts

Summary Hedge fund holdings can help you discover new investment ideas We identified & follow the top biopharma-focused hedge funds Q2 hedge fund holdings reports were released on ~08/14/26 This report focuses on top holdings of top biopharma hedge funds as of 06/30/26 Top Biopharma Hedge Funds At BPIQ we identified the top smid-cap biopharma-focused hedge funds ^1. We updated our database of holding and other info re: these funds with their recently-released data for holdings

Explore BPIQ’s August 2026 hedge fund stock picks, featuring $MIRM and two more biopharma names with key catalysts ahead.

10 Hot Bio/Pharma Stocks on BPIQ’s Q2 Earnings Radar

Explore hedge fund positions and BPIQ model-portfolio overlap in Terns, Centessa, and RAPT before their 2026 biotech M&A deals.

Three hedge fund-backed biopharma picks. One revealed. See why COGT stands out ahead of two FDA decisions, then unlock the other two July 2026 picks.

The bio/pharma IPO market reopened in H1 2026, as we predicted based on the bullish public bio/pharma market starting in the 2nd half of 2025. However, the bio/pharma IPO activity remains far below its historical peak in 2020/2021. BPIQ recorded 15 IPOs in H1 2026, up 114% from seven in H1 2025. This was the highest first-half total since 2021, but only narrowly above the 14 IPOs recorded in H1 2022 and still far below the 61 recorded in H1 2021. Quarterly Activity Shows a Gr

H1 2026 private bio/pharma funding reached its highest total amount invested of the past three years, but the number of funding events declined by almost 33%. Total capital increased slightly compared with H1 2024 and H1 2025, while funding activity remained well below prior-year levels. This points to an investment environment where capital is still available, but fewer companies are securing it. In total, private companies raised approximately $20.3B across 366 funding even

BPIQ has released its H2 2026 Big Movers list, highlighting biotech catalysts with the greatest potential to drive meaningful stock moves. The list includes 18 Big Movers and 79 Suspected Movers. Suspected Movers are catalysts BPIQ identifies as having significant stock-move potential. Big Movers are near-term Suspected Movers where options-implied volatility confirms that the market is pricing in a large move. Elite and APEX subscribers can also see whether a Big Mover is de

Summary Since 2023, BPIQ model portfolios built around biopharma hedge fund consensus holdings have consistently and significantly outperformed the biotech benchmarks XBI and IBB. Want access to our portfolio holdings and other portfolios' info/tools to help you make better biopharma investment decisions? Sign up for Elite or APEX today? Background After extensive back-testing to identify effective strategies for using the consensus holdings of leading institutional investors

BPIQ’s June 2026 Hedge Fund Stock Picks highlight three biopharma catalyst setups. This free version features CLDX, a later-stage immunology pick with pivotal data ahead.

ASCO 2026 was not only about individual readouts. Across five days, the meeting showed where oncology innovation is moving next: more targeted, more biomarker-driven, and increasingly built around complex therapeutic platforms. From BPIQ’s lens, several technology themes stood out. ADCs Stayed at the Center of Oncology Antibody-drug conjugates remained one of the most active modalities across the meeting. Nectin-4 was especially visible, with Corbus, Eli Lilly, and Bicycle Th

ASCO 2026 delivered important updates across hematologic malignancies, lung cancer, breast cancer, gastrointestinal cancers, melanoma, and several rare and difficult-to-treat tumors. Across the meeting, ADCs, bispecific antibodies, cell therapies, radioligand approaches, and increasingly precise biomarker-driven strategies remained at the center of oncology innovation. One presentation stood above the rest. During the Day 3 Plenary Session, Revolution Medicines presented what

Summary Since 2023, BPIQ model portfolios built around biopharma hedge fund consensus holdings have consistently and significantly outperformed the biotech benchmarks XBI and IBB. Want access to our portfolio holdings and other portfolios' info/tools to help you make better biopharma investment decisions? Sign up for Elite or APEX today? Background After extensive back-testing to find to identify the best strategies for using consensus holdings of top institutional investors

ASCO 2026 continued to deliver important clinical updates on Day 2, with presentations spanning cell therapy, lung cancer, breast cancer, gastrointestinal tumors, and rare diseases. While ADCs remained an important part of the meeting, Day 2 highlighted growing momentum behind engineered cell therapies, precision oncology approaches, and several late-stage studies that could influence future standards of care. Cell Therapy Continues Expanding Beyond Hematology Immatics ($IMTX

ASCO 2026 Day 1 Highlights: ADCs, Bispecifics, and Precision Oncology Take Center Stage ASCO 2026 is underway, and Day 1 delivered important updates across hematologic malignancies, lung cancer, genitourinary cancers, and gynecologic oncology. While many presentations reinforced existing standards of care, several datasets highlighted the continued momentum behind antibody-drug conjugates (ADCs), bispecific antibodies, and precision oncology approaches. The day also offered a

ASCO is one of the most important weeks of the year for biotech investors. Clinical updates presented during the meeting can rapidly reshape company narratives, regulatory expectations, partnership interest, and valuation outlooks, especially for small and mid-cap oncology companies. Using BPIQ MCP, we screened for companies where ASCO 2026 presentations could represent meaningful inflection points. The final list includes pivotal Phase 3 datasets, late-stage regulatory setup

Summary Hedge fund holdings can help you discover new investment ideas We identified & follow the top biopharma-focused hedge funds Q1 hedge fund holdings reports were released on ~05/15/26 This report focuses on top holdings of top biopharma hedge funds as of 03/31/26 Top Biopharma Hedge Funds At BPIQ we identified the top smid-cap biopharma-focused hedge funds ^1. We updated our database of holding and other info re: these funds with their recently-released data for holdings

Following our latest portfolio update, a few companies appeared across multiple BPIQ portfolios. Since Top 10A, Top 10B, and Top 15 use different portfolio construction approaches, many stocks appear in only one portfolio. When a company appears across multiple portfolios, it suggests that it ranks highly across multiple versions of our hedge fund consensus framework. Examples from the latest update: DYN → included in Top 10A, Top 10B, and Top 15 ORIC → included in Top 10A an

With the latest hedge fund filings incorporated into our portfolio targets, many subscribers ask a similar question: Why does BPIQ maintain multiple portfolio strategies instead of a single portfolio? The answer is simple. While all of our core portfolios are built from the same foundation, top holdings and consensus positions of biotech-focused hedge funds, portfolio construction matters. As discussed in our recent blog, consensus is the signal, structure is the edge. Years

Biotech investing is not limited by access to information.It is limited by the ability to make consistently better decisions in a highly uncertain environment. Even deep diligence and strong science often fail to translate into consistent outcomes. This led us to shift away from picking individual winners and toward understanding how experienced biotech investors allocate capital. One pattern stood out: Companies held across multiple top biotech-focused hedge funds tend to ou